In late February, the Food amd Drug Administration approved its fifth novel prescription drug or biologic for 2014: AstraZeneca PLC’s Myalept (metreleptin for injection) for the treatment of a very rare fat disorder called generalized lipodystrophy.
Patients with congenital or acquired general lipodystrophy (also known as Lawrence-Seip syndrome) have a near-absence of body fat in the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?